A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT07226843
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Key Dates

Start date
Apr 17, 2026
Status verified
Jun 2026
Primary completion
Apr 30, 2027
Completion
Feb 28, 2030

Study Design

Enrollment
460 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1a-Monotherapy Dose Escalation (Cohort A1)
    LY4584180 monotherapy administered orally
  • Experimental: Phase 1a-Monotherapy Dose Optimization (Cohort A2)
    LY4584180 monotherapy administered orally
  • Experimental: Phase 1b-Dose Expansion-Monotherapy (Cohort B1-B3)
    LY4584180 monotherapy administered orally
  • Experimental: Phase 1b-Dose Expansion-Combination (Cohort B4)
    LY4584180 administered orally in combination with rituximab administered through IV infusion

Primary Outcome Measure

Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities [ Time Frame: Baseline up to Day 28 ]

Central Contacts

  • Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (21)

FacilityCityStateZIPSite coordinators
Mayo Clinic - ScottsdaleScottsdaleArizona85259-
City of HopeDuarteCalifornia91010-
University of California, Los Angeles (UCLA) - Medical CenterLos AngelesCalifornia90059-
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer CenterSan FranciscoCalifornia94158-
Colorado Blood Cancer InstituteDenverColorado80218-
University of Miami - Sylvester Cancer CenterMiamiFlorida33136-
Florida Cancer Specialists - SarasotaSarasotaFlorida34236-
Emory University HospitalAtlantaGeorgia30322-
Dana-Farber Cancer InstituteBostonMassachusetts02215-
Massachusetts General HospitalBostonMassachusetts02114-
Mayo Clinic - RochesterRochesterMinnesota55905-
Columbia UniversityNew YorkNew York10032-
University of RochesterRochesterNew York14618-
The Ohio State University (OSU)ColumbusOhio43210-
Oregon Health & Science University (OHSU)PortlandOregon97239-
Sarah Cannon Research InstituteNashvilleTennessee37203-
Vanderbilt University Medical CenterNashvilleTennessee37212-
Texas Oncology - DFW (Sammons CC)DallasTexas75246-
Baylor College of MedicineHoustonTexas77030-
University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)SeattleWashington98195-
Froedtert Hospital and the Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic - Scottsdale· Scottsdale, AZCity of Hope· Duarte, CAUniversity of California, Los Angeles (UCLA) - Medical Center· Los Angeles, CAUniversity of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center· San Francisco, CAColorado Blood Cancer Institute· Denver, COUniversity of Miami - Sylvester Cancer Center· Miami, FL

Related Studies